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Abstract
Background: The aim of the study was to examine the frequency of factor XIII polymorphism 
among patients with cardiac syndrome X (CSX). 
Methods: This study was designed as a cross-sectional and observational study. Forty-eight 
female patients with CSX and 36 controls matched by age, gender, diabetes, and hypertension 
were studied. CSX was defined as typical chest pain during rest or effort, abnormal test result 
for exercise ECG, and presence of angiographically normal epicardial coronary arteries after 
ruling out inducible spasm. Factor XIII gene polymorphism was investigated by using CVD 
Strip Assay (ViennaLab Diagnostic GmbH) commercial kit.
Results: The frequency of factor XIII (Val/Leu + Leu/Leu) mutation was significantly higher 
in patients with CSX (43%) than in controls (19%) (p = 0.02). Frequency of the Leu allele 
was significantly higher in the patient group (23.5% vs. 11.1%, p = 0.04). Factor XIII (Val/ 
/Leu + Leu/Leu) mutation (p = 0.01, OR = 3.42; 95% CI 1.22–9.58) and smoking (p = 0.04,  
OR = 3.33, 95% CI 1.05–10.58) were identified as independent predictors of the disease in 
multivariate regression analysis.
Conclusions: This study indicates that there is an evidence for association between factor XIII 
Val34Leu polymorphism and CSX. (Cardiol J 2014; 21, 1: 6–10)
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Introduction
Cardiac syndrome X (CSX) is a clinical entity 
of angina-like chest pain and positive response to 
cardiac stress test without coronary artery disease 
(CAD). Studies showed that the prognosis of CSX, 
which is considered in the class of stable angina 
pectoris, was generally better than the prognosis 
of the patients with acute coronary syndrome and 
patients detected to have a disorder in coronary 
angiography [1, 2]. Myocardial ischemia due to 
coronary microvascular dysfunction and increa-
sed sensitivity to pain are the mechanisms pre-
dominantly considered to be responsible for the 
pathophysiological process, while reasons such 
as insulin resistance, estrogen deficiency, and 
autonomous dysfunction are also being discussed 
for etiology [3].
Factor XIII (FXIII) as a plasma transglutami-
nase, plays a role in the stabilization of fibrin which 
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is an important step of the coagulation cascade. 
FXIII Val34Leu polymorphism occurs as a result 
of the substitution of amino acid leucine (Leu) for 
valine (Val) at position 34 of the FXIII gene [4]. 
Several studies have demonstrated that this poly-
morphism was protective against CAD, as well as 
myocardial infarction [5, 6]. However, its relation 
to CSX was not investigated. In this study, our aim 
is to examine the frequency of FXIII polymorphism 
among patients with CSX who are known to have 
an overall good prognosis.
Methods
This study was designed as a cross-sectional 
and observational study. Forty-eight female pa-
tients diagnosed with CSX who were admitted to 
Kartal Koşuyolu Advanced Training and Research 
Hospital and a control group of 36 women were 
recruited into the study between March 2008 
and May 2009, after the approval of local ethics 
committee.
CSX was defined as typical chest pain during 
rest or effort, abnormal test result for exercise ECG, 
and presence of angiographically normal epicardial 
coronary arteries. Control group was selected 
from volunteers presented to our hospital with the 
complaint of atypical angina who had normal result 
from exercise ECG and had similar risk profile with 
the patients (diabetes, hypertension, age, gender).
Patients who had abnormal echocardiography 
findings (dilated cardiomyopathy, hypertrophic car-
diomyopathy, valvular cardiac disease, congenital 
heart disease, left ventricular hypertrophy, right 
ventricular hypertrophy) or history of peripheral 
vascular disease, chronic renal failure, hepatic 
failure, and thyroid dysfunction were excluded 
from the study. All exclusion criteria were applied 
also to the control group. Both patient and control 
groups were clinically examined and evaluated 
with rest ECG.
Both patient and control groups had 2-dimen-
sional and Doppler echocardiography according 
to the recommendations of American Society of 
Echocardiography [7], patient exclusion criteria 
were evaluated.
Whole blood samples were obtained in EDTA 
tubes to study FXIII gene polymorphism. Total 
genomic DNA from peripheral whole blood samples 
of the patients were isolated with the GenXtract so-
lution supplied with the kit. After that, target DNA 
regions were amplified with multiplex polymerase 
chain reaction by using biotin-labeled primers. 
Amplified products were then checked in agarose 
gel 3%. Following the detection of the amplicons of 
the related genes, PCR products were hybridized 
to test strip containing nucleotide probes specific 
to the immobilized allele on the nitrocellulose 
membrane by using CVD Strip Assay (ViennaLab 
Diagnostic GmbH) commercial kit. Hybridization 
process was performed in Profiblot T48 (Tecan) 
hybridization device. Sequences labeled with hy-
bridized biotin were detected by using streptavidin-
-alkaline phosphatase and color substrates.
Statistical analysis
Mean ± standard deviation was used for con-
tinuous variants, while percentages were used for 
categorical variants. Unpaired t test was used to 
test the difference between the continuous variants 
which showed normal distribution between patient 
and control groups.
Normal distribution was tested with one sam-
ple Kolmogorov-Smirnov test. Pearson c2, Fisher’s 
exact test and Continuity Correction (Yate’s Cor-
rection) test were used to test the categorical va-
riants. The variants for which evident significance 
(p < 0.1) were found in the univariate analysis were 
included in multivariate logistic regression analysis 
to determine the independent components of CSX. 
P-value of < 0.05 was considered significant for all 
tests. Statistical Package for the Social Sciences 
(SPSS version 11.0, SPSS Inc., Chicago, IL, USA) 
was used.
Results
The characteristics of the patients participa-
ting in the study are shown in Table 1. Accordin-
gly, there was no difference between patient and 
control groups except for the history of smoking 
(p = 0.04).
Genotype and allele frequency of FXIII 
Val34Leu polymorphism among healthy 
control group
Val/Val, Val/Leu and Leu/Leu genotypes were 
detected in 29 (80%), 6 (16%) and 1 (2%) of the pa-
tients, respectively. Allele frequencies were 88.9% 
and 11.1% for Val and Leu, respectively (Table 2).
Genotype and allele frequency of FXIII  
Val34Leu polymorphism among patients 
with CSX
Val/Val, Val/Leu and Leu/Leu genotypes were 
shown in 27 (56%), 19 (39%) and 2 (4%) of the patients 
with CSX, respectively. Allele frequencies were 76.5% 
and 23.5% for Val and Leu, respectively (Table 2).
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Frequency of Leu allele was significantly 
higher in patients with CSX compared to the con-
trol group (23.5% vs. 11.1%; p = 0.04, OR = 2.453, 
95% CI 1.02–5.86).
Multivariate analysis model, which was gene-
rated according to the results of the univariate ana-
lysis in the aim to determine the predictors of CSX 
disease, included smoking and FXIII polymorphism 
Table 3. As a result, both FXIII polymorphism 
(Val/Leu + Leu/Leu) (p = 0.01, OR = 3.42, 95% 
CI 1.22–9.58) and smoking (p = 0.04, OR = 3.33, 
9.5% CI 1.05–10.58) were found predictors of the 
disease, while FXIII polymorphism was a stronger 
predictor (Table 4).
Discussion
In our study, Leu allele frequency was identi-
fied significantly higher in patients with CSX than 
the control group, and FXIII Val34Leu polymor- 
phism was found to be the most important factor 
as an independent predictor of the disease.
Lack of a standard diagnostic criteria and con-
sensus on pathophysiology along with inefficient 
treatment options make CSX a despairing disease 
for both patients and physicians. In order to explain 
Table 3. Univariate analysis for major risk factor 
in cardiac syndrome X.
Odds ratio  
(95% CI)
P*
Diabetes 0.9 (0.32–2.63) 1
Hypertension 0.8 (0.37–2.13) 0.97
Smoking 3.1 (1.01–9.49) 0.04
Factor XIII mutation 
(Val/Leu + Leu/Leu)
3.2 (1.18–8.78) 0.02
Hyperlipidemia 0.8 (0.35–2.10) 0.92
*c2 test; CI — confidence interval; Val — valine; Leu — leucine
Table 4. Multivariate analysis for independent 
predictors.
Beta P Odds ratio 
(95% CI)
Factor XIII mutation 
(Val/Leu + Leu/Leu)
1.23 0.01 3.42  
(1.22–9.58)
Smoking 1.20 0.04 3.33  
(1.05–10.58)
Hosmer and Lemeshow Test: p = 0.525; Nagelkerke R2: 0.155;  
CI — confidence interval; Val — valine; Leu — leucine
Table 1. General characteristics of patients and controls.
Patients (n = 48) Controls (n = 36) P
Age [year] 53 ± 6 54 ± 8 0.57* 
Body mass index [kg/m2] 29.83 ± 3.90 31.19 ± 4.11 0.13*
Hypertension [%] 41 44 0.97**
Diabetes [%] 20 22 1***
Smoking [%] 33 13 0.04**
Hyperlipidemia [%] 38 35 0.92**
*Unpaired student t test was used; **Fisher’s Exact test was used; ***Continuity Correction test was used
Table 2. Frequency of Val-Leu allele and genetic variations.
Patients (n) Controls (n) P
Val/Val 56% (27) 80% (29) 0.06*
Val/Leu 39% (19) 16% (6)
Leu/Leu 4% (2) 2% (1)
Val/Leu + Leu/Leu 43% (21) 19% (7) 0.02**
Odds ratio = 3.22, 95% CI 1.18–8.78
Val 76.5% 88.9% 0.04**
Leu 23.5% 11.1%
Odds ratio = 2.453, 95% CI 1.02–5.86
*Pearson c2 test was used; **Fisher’s Exact test was used; Val — valine; Leu — leucine
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the pathophysiological abnormality, various theo-
ries such as abnormal coronary flow reserve [8], 
insulin resistance [9], enhanced red cell sodium-
-hydrogen exchange [10], and abnormal cardiac 
sensitivity [11] were suggested. The most proven 
and accepted ideas are endothelial dysfunction 
and inflammation, and increased sensitivity to 
pain [3, 12]. Endothelial dysfunction reduces the 
release of anti-inflammatory and anti-thrombogenic 
factors and reduces the availability of nitric oxide 
by disrupting the vasoconstriction/vasodilatation 
balance [13]. Endothelial dysfunction has also 
a prognostic value since patients with chest pain 
having normal or almost normal coronary arteries 
showed increased frequency of cardiovascular 
events during follow-ups [14]. Long-term follow-up 
results of the patients with CSX were reported as 
highly good due to the lack of major acute corona-
ry events (as cardiac death and acute myocardial 
infarction) [1], however the persistence of the 
symptoms, reduced quality of life and frequent 
hospital admissions due to inefficient treatments 
led to discussions on good prognosis.
In fact, the risk profile of this patient group 
is similar to the patients with occlusive CAD 
(conventional cardiovascular risk factors, incre-
ased inflammation, endothelial dysfunction etc.). 
Investigations on mechanisms are ongoing to 
understand why these patients do not have critical 
atherosclerotic lesions in coronary arteries and do 
not develop acute coronary events despite having 
evidence on coronary microvascular dysfunction. 
Studies are focused on platelet reactivity to explain 
this good prognosis [15, 16]. Platelet reactivity 
following exercise or mental stress was measured 
in normal subjects, patients with CAD and patients 
with CSX, and it was demonstrated that reactivity 
was increased in CAD patients, remained the same 
in normal subjects and decreased in patients with 
CSX [17]. These findings put vascular protection 
and potential protective factors against acute 
thrombotic events on the agenda.
FXIII, which is also called a fibrin stabilizing 
factor due to its essential role in maintaining ho-
meostasis, is an enzyme effective in the last step 
of the coagulation cascade. FXIII is a zymogen 
with tetrameric (A2B2) structure which consists 
of 2 active A subunits and 2 inhibitory B subunits, 
and is found in plasma as a pro-enzyme [18]. FXIII 
forms cross-links between fibrin monomers by 
transglutaminase activity making the clot more 
resistant to fibrinolysis [19]. Congenital FXIII is 
a rare autosomal recessive disorder resulting in 
hemorrhagic diathesis. It is characterized by subcu-
taneous and intramuscular hematomas, intracranial 
hematomas, and defective wound healing [20]. 
The most frequent mutation in the genes coding 
for the FXIII is G-T transition in the exon of the 
gene coding for FXIIIA [4]. This mutation causes 
valine to convert to leucine in A subunit (FXIII AL) 
[4]. This mutation is defined as FXIII Val34Leu 
polymorphism due to high prevalence among po-
pulation [4]. As a result of this mutation, thrombin 
activation of FXIII-A subunit and stability of fibrin 
will be decreased, and alternatively its interaction 
with other coagulation factors will be affected [6].
The studies focused on the assumption that 
the presence of FXIII Leu34 allele might have pro-
tective effects against arterial and venous thrombo-
sis [21–23]. In a study including 398 patients with 
acute coronary syndrome and 196 healthy control 
subjects, it was demonstrated that FXIII Leu inci-
dence was significantly low in the patient group and 
suggested that this polymorphism was protective 
against acute coronary syndrome [6]. Kohler et al. 
[6] concluded that the mutation in FXIII, a fibrin 
stabilizer, would lead to ineffective cross-linking 
and formation of weaker fibrin structures. In our 
study, both homozygote and heterozygote poly-
morphism of Leu34 allele was identified frequently 
in the patient group compared to the control group. 
CSX occurrence increases in individuals with Leu 
allele, whereas the position of this mutation in the 
benign prognosis of the disease may be associated 
with the ineffective function in the coagulation 
cascade of FXIII.
Smoking is believed to contribute to etiology 
similarly to other risk factors of CAD due to pos-
sible endothelial dysfunction [24]. Therefore, 
smoking secession is recommended together with 
reducing the atherosclerotic risk factors at the 
beginning of the non-pharmacological treatment of 
the disease [25]. Our study also identified smoking 
as an independent predictor for CSX together with 
FXIII mutation, supporting the literature.
CSX is considered among subgroups of stable 
CAD and it is emphasized that it has a better pro-
gnosis than the patient group with proven occlusive 
coronary lesion. We think that the presence of this 
mutation in CSX may be associated with a patho-
physiological process in which microvascular bed 
is affected, while macrovascular bed is preserved.
It is the first study on patients with CSX re-
lating FXIII Val34Leu polymorphism. A limitation 
to our study is the small number of patients. Large 
studies conducted on great number of patients 
will clarify the effect of this polymorphism on the 
pathogenesis and prognosis of CSX.
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Conclusions
This study indicates that there is an evidence 
for association between factor XIII Val34Leu poly-
morphism and CSX.
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